Nomura Micro Science Co., Ltd.
【Nomura Micro Science】 Fiscal Year 2026 Earnings Revision | Cash Flow Adjustment
Nomura Micro Science has revised its fiscal year 2026 financial results, with operating cash flow adjusted to ¥4,363 million. Details of net income and cash flow have also been corrected, leading to a reassessment of the financial position.
Key Figures
- Cash flow from operating activities: ¥4,363 million
- Cash and cash equivalents at end of period: ¥9,933 million
- Consolidated cash flow: ¥4,363 million
AI要約
Revisions to Financial Results
Nomura Micro Science has corrected certain figures in its fiscal year 2026 financial summary due to previous inaccuracies. Corrections were made to the cash flow amounts, the deferred tax liabilities in fixed liabilities on the consolidated balance sheet, and various items in the cash flow statement. As a result, the end-of-period balance of cash and cash equivalents stands at ¥9,933 million. These adjustments reflect a reassessment of the company's cash flow and asset-liability position compared to the previous year. The corrections were identified during the audit review process, aiming to ensure precise financial disclosures.
Financial Status and Future Outlook
Post-correction financial statements show changes in operating, investing, and financing cash flows, with operating cash flow revised to ¥4,363 million. Accurate understanding of net income and cash flow is needed to revise management strategies and capital plans. The company intends to continue providing accurate financial disclosures and maintain investor trust.
Nomura Micro Science Inc.
Company overview · Stock price · Financial data · All IR
